Puration Inc (OTCMKTS:PURA) shares are higher on the year, but were significantly higher early in the quarter. Shares overall have been very volatile since August, 2016 and trading this sub penny is not for the weak of heart. It moves around and is liquid.
The company had news and said recently that NCM Biotech has licensed to PURA, the right to utilize NCM Biotech’s patented cannabis extraction process to produce cannabis extracts for infusion into recreational, fitness wellness, alternative medicine and beauty products. NCM Biotech exclusively owns U.S. Patent No. 9,199,960, entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.” The license of the process to PURA is the first and only license NCM Biotech has executed.
“I have received doctor feedback from more than one of our research initiatives, that extracts coming from NCM Biotech’s patented process are superior in purity and quality to any other available cannabis extracts,” said Frederick Ferri, CEO and Founder of NCM Biotech. “Some feedback has specifically indicated that a number of our candidate pharmaceutical products under development, have a greater efficacy potential than GW Pharmaceutical products and candidate products. We are very enthusiastic about working with Puration, to rapidly ramp-up non-pharmaceutical extract sales offering the highest quality extracts available in the growing cannabis market, and in turn using those sales to fund our ongoing pharmaceutical product development and FDA approval process.”
Puration Inc (OTCMKTS:PURA) as you are by now aware – sits squarely in a hot sector. The Cannabis sector is on fire, and any products introduced into the retail space automatically attach and attractive industry multiple. PURA recently launched its first cannabis infused consumer product. PURA introduced EVERx CBD Infused Bottled Water at the recent Arnold Schwarzenegger Annual Sports Festival, in Columbus Ohio. PURA plans to introduce three new EVERx CBD Infused sports nutritional supplement products later this month, in conjunction with the annual cannabis 420 celebration.
Find out when $PURA stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
“The license agreement announced today is a substantial and strategic update to the joint venture agreement under which PURA and NCM have already been working,” said Brian Shibley, CEO of Puration. “The license agreement is a more reliable and financeable asset than the joint venture agreement. With the license agreement, we anticipate securing conventional financing to build a commercial extraction lab that can support the magnitude of sales interest we have already generated, with just the introduction of one product so far. In fact, look for the first of two anticipated lab facility announcements later this month.”
The company also set up a quality team which includes John N. Gaitanis, MD., Director of Child Neurology at Tufts Medical Center/Floating Hospital for Children; Lloyd R. Saberski, M.D., Associate Professor of Anesthesiology and Chronic Pain Management, Yale University, and John McMichael, Ph.D., President & CEO Beech Tree Labs. Research and development with NCM Biotech’s patented process has demonstrated a high potential for bringing FDA approved pharmaceutical products to market, for the treatment of multiple neurological disorders and cancer.
The license agreement with PURA is specifically designed to accelerate funding for the FDA approval process, through proceeds generated by PURA’s sales of extracts for infusion into non-pharmaceutical consumer products. Beech Tree Labs is slated to manage the FDA approval process.
Puration, Inc. (OTCMKTS:PURA) is a volatile name to watch, and many who trade the space enjoy trading these kinds of stocks in the sub-penny sector which is prone to have spikes up and down. You know what your getting with PURA, and the best thing to do is strap in and enjoy the ride, but nearly all stocks in this sector have some level of extensive price swings and if you trade these on a daily basis you know how momentum can push these stocks from undervalued to overvalued in an instant. Best advice on all sub-penny Cannabis sector traders is to trade with caution and be flat at the end of the day. For continuing coverage on shares of $PURA stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!